Vertex Pharmaceuticals (VRTX) revenue and earnings history
Vertex Pharmaceuticals reported revenue of $12B for fiscal 2025 (year ended Dec 31, 2025), +8.9% on the year before, and net income of $3.95B.
Over 17 years, from fiscal 2008 to fiscal 2025, revenue grew at a compound rate of +28.2% a year.
Revenue and net income, 18 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $12B+8.9% | $4.17B | $3.95B | $3.63B | $438M | $3.19B | $686M | $2.02B | — | $5.08B | $0 | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Vertex Pharmaceuticals (VRTX) on OQRO.
Common questions
What was Vertex Pharmaceuticals's revenue in fiscal 2025?
$12B for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 13, 2026. That is +8.9% on fiscal 2024 ($11B).
How fast has Vertex Pharmaceuticals's revenue grown?
From $176M in fiscal 2008 to $12B in fiscal 2025: a compound annual growth rate of +28.2% over 17 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Vertex Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
